The impact of HLA-G 3′ UTR variants and sHLA-G on risk and clinical correlates of schizophrenia
Version 2 2024-06-06, 09:36Version 2 2024-06-06, 09:36
Version 1 2016-10-10, 11:53Version 1 2016-10-10, 11:53
journal contribution
posted on 2024-06-06, 09:36authored byA Rajasekaran, V Shivakumar, SV Kalmady, JC Narayanaswamy, M Subbana, D Venugopal, AC Amaresha, G Venkatasubramanian, Michael BerkMichael Berk, M Debnath
The Major Histocompatibility Complex (MHC)/Human Leukocyte Antigen (HLA) is known to influence the pathogenesis of several complex human diseases resulting from gene-environmental interactions. Recently, it has emerged as one of the risk determinants of schizophrenia. The HLA-G protein (a non-classical MHC class I molecule), encoded by the HLA-G gene, is shown to play important role in embryonic development. Importantly, its genetic variations and aberrant expression have been implicated in pregnancy complications like preeclampsia, inflammation, and autoimmunity. Converging evidence implicates these phenomena as risk mechanisms of schizophrenia. However, the functional implications of HLA-G in schizophrenia are yet to be empirically examined. The impact of two functional polymorphisms [14bp Insertion/Deletion (INDEL) and +3187 A>G] and soluble HLA-G (sHLA-G) levels on schizophrenia risk was evaluated. In this exploratory study, the Ins/Ins genotype of 14bp INDEL was found to confer a strong risk for schizophrenia. Further, low levels of sHLA-G were shown to have a significant impact on Clinical Global Impression (CGI) severity in people with schizophrenia.